Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH.

Mednet Member

Hematology · Stanford Univeristy

The thrombosis versus bleeding risk ratio should be weighed. The risk of VTE recurrence or propagation is highest in the first 30 days and we know that thrombocytopenia does not attenuate this risk. Providers should favor anticoagulation. In the case of cancer-associated thrombosis and chemotherapy-...